Chimerix 2017 Corporate Overview – Brincidofovir Antiviral

Chimerix is a biopharmaceutical company developing brincidofovir (BCV), a broad-spectrum antiviral targeting life-threatening viral infections including herpes, adenovirus, and smallpox. The drug is available in oral and IV formulations with patent protection through 2034 and potential applications in stem cell transplant recipients and other immunocompromised populations.